<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadofosveset (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadofosveset (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadofosveset (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11953" href="/d/html/11953.html" rel="external">see "Gadofosveset (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F10117337"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic systemic fibrosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the drugs. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with noncontrast-enhanced magnetic resonance imaging (MRI) or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.</p>
<p style="text-indent:-2em;margin-left:2em;">The risk for NSF appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute per 1.73 m<sup>2</sup>) or acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:2em;">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk of chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at highest risk for NSF, do not exceed the recommended gadofosveset dose. Allow a sufficient period of time for elimination of the drug from the body prior to readministration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5219405"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent;</li>
<li>
                        Gadolinium-Containing Contrast Agent;</li>
<li>
                        Linear Gadolinium-Based Contrast Agent;</li>
<li>
                        Radiological/Contrast Media (Nonionic, Low Osmolality);</li>
<li>
                        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F5219558"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63e4703d-ebe7-40fd-a219-ba05aed93aa1">Angiography imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Angiography imaging:</b> IV: 0.03 mmol/kg (0.12 mL/kg).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990348"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">GFR ≥60 mL/kg/m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR &lt;60 mL/kg/m<sup>2</sup>: 0.01 to 0.02 mmol/kg; use with caution. Risk for NSF development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17213364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17213364'])">Ref</a></span>). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first to third hemodialysis sessions, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17213364','lexi-content-ref-11350296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17213364','lexi-content-ref-11350296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653466','lexi-content-ref-17213364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653466','lexi-content-ref-17213364'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987719"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Limited data suggest pharmacokinetics of gadofosveset in patients with hepatic disease do not differ substantially.</p></div>
<div class="block doe drugH1Div" id="F5219559"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F5219416"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasodilation (3%), hypertension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (4%), paresthesia (3%), burning sensation (2%), dizziness (1%), sensation of cold (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (4%), dysgeusia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, nephrogenic systemic fibrosis (NSF/NFD), prolonged QT interval on ECG</p></div>
<div class="block coi drugH1Div" id="F5219412"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of prior hypersensitivity to any gadolinium-based contrast agent.</p></div>
<div class="block war drugH1Div" id="F5219413"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>).</b> The risk appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT<sub>c</sub> prolongation: Rare cases of QT<sub>c</sub> prolongation have been observed with gadofosveset use. Data from pooled safety studies have demonstrated that the administration of gadofosveset resulted in minimal changes to the QT<sub>c</sub> interval as compared to placebo (means of 2.8 msec and 3.2 msec respectively). Consider baseline and follow up ECG in patients at increased risk of arrhythmias due to QT<sub>c</sub> prolongation (eg, underlying cardiac disease, concurrent medications). Patients should be monitored for at least 1 hour after the administration of gadofosveset.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Dosage reductions may be necessary. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p></div>
<div class="block geq drugH1Div" id="F5219403"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324146"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ablavar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">244 mg/mL (10 mL): $145.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5219562"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer as an intravenous bolus injection over a period up to 30 seconds through a dedicated IV line separate from other medications. Flush line with 25-30 mL NS after administration to ensure complete injection of medium. Imaging should be completed within 1 hour of injection.</p></div>
<div class="block use drugH1Div" id="F5219407"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Angiography imaging:</b> Contrast medium agent used in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.</p></div>
<div class="block mst drugH1Div" id="F5219400"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vasovist [Hungary, Turkey] may be confused with Gadavist brand name for gadobutrol [U.S.]; Gadovist brand name for gadobutrol [Canada and multiple international markets]; Magnevist brand name for gadopentetate dimeglumine [U.S., Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299378"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F5219542"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5219408"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gadolinium-based contrast agents may cross the placenta (ACOG 723 2017; ACR 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 723 2017). In addition, use should only be considered if information needed from the study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2018).</p></div>
<div class="block brc drugH1Div" id="F5219411"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents may be present in breast milk (ACOG 723 2017; ACR 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption after use (ACOG 723 2017; ACR 2018). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2018). The manufacturer does not recommend use in breastfeeding women unless diagnostic imaging is essential and cannot be obtained by noncontrast MRA (consider the long half-life of gadofosveset).</p></div>
<div class="block mop drugH1Div" id="F5219565"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline ECG if risk factors for QT<sub>c</sub> prolongation/torsade de pointes; baseline electrolytes (including potassium, calcium and magnesium); screen for renal impairment (all patients); baseline renal function in patients at risk of NSF and follow-up evaluation with renal dysfunction; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of NSF/NFD (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye).</p></div>
<div class="block pha drugH1Div" id="F5219546"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gadofosveset is a gadolinium-containing paramagnetic agent that reversibly binds to albumin in the plasma. Exposure to an external magnetic field induces a large local magnetic field in exposed blood vessels. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device. The binding of gadofosveset to albumin prolongs the period of time gadofosveset resides intravascularly, enhances T1 relaxivity up to 10 times greater than nonprotein bound gadolinium chelates and provides a longer imaging window. </p></div>
<div class="block phk drugH1Div" id="F5219548"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 5 to 7 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 148 ± 16 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 80% to 87% (predominantly to albumin)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Negligible</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 16.3 ± 2.6 hours; moderate renal impairment: 49 hours; severe renal impairment: 70 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (79% to 94% as unchanged drug); feces (~5%)</p></div>
<div class="block phksp drugH1Div" id="F51196083"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance decreases substantially as renal function decreases. AUC increased 1.75-fold in patients with moderate (CrCl 30 to 50 mL/minute) and 2.25-fold in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038898"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vasovist</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vasovist</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ablavar | Vasovist</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Ablavar (gadofosveset trisodium) [pescribing information]. North Billerica, MA: Lantheus; August 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR) Committee of Drugs and Contrast Media. ACR manual on contrast media. 2018. Available at https://www.acr.org
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902904">
<a name="11902904"></a>Caravan P, Cloutier NJ, Greenfield MT, et al, “The Interaction of MS-325 With Human Serum Albumin and Its Effect on Proton Relaxation Rates,” <i>J Am Chem Soc</i>, 2002, 124(12): 3152-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/11902904/pubmed" id="11902904" target="_blank">11902904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23345200">
<a name="23345200"></a>Expert Panel on MR Safety, "ACR Guidance Document on MR Safe Practices: 2013," <i>J Magn Reson Imaging</i>, 2013, 37(3):501-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/23345200/pubmed" id="23345200" target="_blank">23345200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653466">
<a name="9653466"></a>Joffe P, Thomsen HS, and Meusel M, "Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis," <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/9653466/pubmed" id="9653466" target="_blank">9653466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17213364">
<a name="17213364"></a>Kuo PH, Kanal E, Abu-Alfa AK, et al, "Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis," <i>Radiology</i>, 2007, 242(3):647-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/17213364/pubmed" id="17213364" target="_blank">17213364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9577506">
<a name="9577506"></a>Lauffer RB, Parmelee DJ, Dunham SU, et al, “MS-325: Albumin-Targeted Contrast Agent for MR Angiography,” <i>Radiology</i>, 1998, 207(2): 529-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/9577506/pubmed" id="9577506" target="_blank">9577506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350296">
<a name="11350296"></a>Okada S, Katagiri K, Kumazaki T, et al, “Safety of Gadolinium Contrast Agent in Hemodialysis Patients,” <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/11350296/pubmed" id="11350296" target="_blank">11350296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14593194">
<a name="14593194"></a>Perreault P, Edelman MA, Baum RA, et al, “MR Angiography with Gadofosveset Trisodium for Peripheral Vascular Disease: Phase II Trial,” <i>Radiology</i>, 2003, 229(3):811-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/14593194/pubmed" id="14593194" target="_blank">14593194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17035873">
<a name="17035873"></a>Shamsi K, Yucel EK, and Chamberlin P, “A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose,” <i>Invest Radiol</i>, 2006, 41(11): 822-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadofosveset-united-states-not-available-drug-information/abstract-text/17035873/pubmed" id="17035873" target="_blank">17035873</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8833 Version 137.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
